The utility of serum N-ERC/mesothelin as a biomarker of ovarian carcinoma

Saeki, Harumi; Hashizume, Akane; Izumi, Hiroshi; Suzuki, Fujihiko; Ishi, Kazuhisa; Nojima, Masanori; Hino, Okio

doi:10.3892/ol.2012.796

Cited by 6 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, the serum N-ERC/mesothelin concentration was not found to be a useful diagnostic marker of gastric cancer. Previously, we and others have shown that the serum N-ERC/mesothelin level is useful for diagnosing human mesothelioma and ovarian cancer ( 7 , 9 , 19 , 22 , 23 ). Conversely, in a previous study we did not find any significant difference in the serum concentration of N-ERC/mesothelin between pancreatic ductal carcinoma patients and healthy controls ( 8 ).…”

Section: Discussionmentioning

confidence: 99%

ERC/mesothelin is expressed in human gastric cancer tissues and cell lines

et al. 2013

Self Cite

View full text Add to dashboard Cite

ERC/mesothelin is expressed in mesothelioma and other malignancies. The ERC/mesothelin gene (MSLN) encodes a 71-kDa precursor protein, which is cleaved to yield 31-kDa N-terminal (N-ERC/mesothelin) and 40-kDa C-terminal (C-ERC/mesothelin) proteins. N-ERC/mesothelin is a soluble protein and has been reported to be a diagnostic serum marker of mesothelioma and ovarian cancer. Gastric cancer tissue also expresses C-ERC/mesothelin, but the significance of serum N-ERC levels for diagnosing gastric cancer has not yet been studied. We examined the latter issue in the present study as well as C-ERC/mesothelin expression in human gastric cancer tissues and cell lines. We immunohistochemically examined C-ERC/mesothelin expression in tissue samples from 50 cases of gastric cancer, and we also assessed the C-ERC/mesothelin expression in 6 gastric cancer cell lines (MKN-1, MKN-7, MKN-74, NUGC-3, NUGC-4 and TMK-1) using reverse transcription-polymerase chain reaction, flow cytometry, immunohistochemistry and immunoblotting. We also examined the N-ERC/mesothelin concentrations in the supernatants of cultured cells and in the sera of gastric cancer patients using an enzyme-linked immunosorbent assay (ELISA). N-ERC/mesothelin was detected in the supernatants of 3 gastric cancer cell lines (MKN-1, NUGC-4 and TMK-1) by ELISA, but its concentration in the sera of gastric cancer patients was almost same as that observed in the sera of the normal controls. In the gastric cancer tissues, C-ERC/mesothelin expression was associated with lymphatic invasion. N-ERC/mesothelin was secreted into the supernatants of gastric cancer cell lines, but does not appear to be a useful serum marker of gastric cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

ERC/mesothelin is expressed in human gastric cancer tissues and cell lines

et al. 2013

Self Cite

View full text Add to dashboard Cite

show abstract

“…The human homolog of rat Erc is the Mesothelin / megakaryocyte potentiating factor ( MPF ) gene [6] – [8] . ERC/mesothelin is also expressed in ovary and pancreas carcinoma tissue in humans [9] – [12] . N-ERC/mesothelin is considered to be relevant in monitoring chemotherapeutic response in patients with mesothelioma [13] , [14] .…”

Section: Introductionmentioning

confidence: 99%

Rat N-ERC/Mesothelin as a Marker for In Vivo Screening of Drugs against Pancreas Cancer

et al. 2014

Self Cite

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDA) is a highly lethal disease, which is usually diagnosed in an advanced stage. We have established transgenic rats carrying a mutated K-ras gene controlled by Cre/loxP activation. The animals develop PDA which is histopathologically similar to that in humans. Previously, we reported that serum levels of N-ERC/mesothelin were significantly higher in rats bearing PDA than in controls. In the present study, to determine whether serum levels of N-ERC/mesothelin correlated with tumor size, we measured N-ERC/mesothelin levels in rats bearing PDA. Increased serum levels of N-ERC/mesothelin correlated with increased tumor size. This result indicates an interrelationship between the serum level of N-ERC/mesothelin and tumor size. We next investigated the effect of chemotherapy on serum N-ERC/mesothelin levels. Rat pancreatic cancer cells were implanted subcutaneously into the flank of NOD-SCID mice. In the mice treated with 200 mg/kg gemcitabine, tumor weight and the serum level of N-ERC/mesothelin were significantly decreased compared to controls. These results suggest that serum N-ERC/mesothelin measurements might be useful for monitoring response to therapy.

show abstract